Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories
Marketwire Canada - Tue Jun 07, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 7, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma to Request Regulatory Guidance for Filing for Its FlutiCare Product in Europe for the Treatment of Allergic Rhinitis
Marketwired - Thu Jun 02, 9:18AM CDT
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Marketwire Canada - Wed Jun 01, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 1, 2016) - Innovus Pharmaceuticals Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multi-billion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ -- a leading prescription nasal steroid -- in February 2015, the company expects to receive regulatory approval later this year.
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision
Marketwired - Tue May 31, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma Signs Exclusive License and Distribution Agreement With BroadMed for EjectDelay in Lebanon
Marketwire Canada - Wed May 25, 5:05AM CDT
SAN DIEGO, CA--(Marketwired - May 25, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion Testosterone Replacement Market
Marketwired - Tue May 24, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 24, 2016) - Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.
LLY: 74.70 (-0.14), ABBV: 63.10 (+0.28)
SeeThruEquity Issues Update Note on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) with a Price Target of $0.91
ACCESSWIRE - Mon May 23, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on Innovus Pharmaceuticals, Inc. (OTCQB: INNV).
Innovus Pharma CEO Provides Shareholder Update and Conference Call
Marketwire Canada - Fri May 20, 5:10AM CDT
SAN DIEGO, CA--(Marketwired - May 20, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma CEO Provides Shareholder Update
Marketwired - Mon Apr 04, 9:00AM CDT
Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma CEO Interviewed on CEOLIVE.Tv
Marketwired - Tue Mar 22, 9:00AM CDT
Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharma Announces the Availability of Androferti in the U.S.
Marketwired - Thu Mar 17, 9:00AM CDT
Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
Innovus Pharmaceuticals Announces the Filing of the Product License to Commercialize Androferti With Health Canada
Marketwired - Tue Mar 08, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"